Glutathione and N-acetylcysteine conjugates of α-methyldopamine produce serotonergic neurotoxicity: Possible role in methylenedioxyamphetamine- mediated neurotoxicity

Chemical Research in Toxicology

Volumn 12, Issue 12, 1999, Pages 1150-1157

  Bai, Fengju ^a   Lau, Serrine S ^a   Monks, Terrence J ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; ACETYLCYSTEINE; ALPHA METHYLDOPAMINE; GLUTATHIONE PEROXIDASE; SEROTONIN; SULFIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; MALE; NERVE ENDING; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; RAT; SEROTONINERGIC SYSTEM;

3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; BRAIN; DEOXYEPINEPHRINE; GLUTATHIONE; HYDROXYINDOLEACETIC ACID; MALE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN AGENTS;

ANIMALIA; MEDA;

EID: 0033386744     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx990084t     Document Type: Article

References (51)

1. Thiessen, P. N., and Cook, D. A. (1973) The properties of 3,4-methylenedioxyamphetamine (MDA). I. A review of the literature. Clin. Toxicol. 6, 45-52.
2. Kovar, K. A. (1998) Chemistry and pharmacology of hallucinogens, entactogens and stimulants. Pharmacopsychiatry 31 (Suppl. 2), 69-72.
3. Cuomo, M., Dyment, P., and Gammino, V. (1994) Increasing use of ecstasy (MDMA) and other hallucinogens on a college campus. Journal of American College Health 42, 271.
4. Johnson, L. D., O'Malley, P. M., and Bachman, J. G. (1997) National survey results on drug use from the Monitoring the Future study, 1975-1995. Vol. 2. College students and young adults, National Institutes on Drug Abuse, Rockville, MD.
5. Henry, J. A., Jeffreys, K. J., and Dawling, S. (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine. Lancet 340, 384-387.
6. Stone, D. M., Hanson, G. R., and Gibb, J. W. (1986) The effects of 3,4-methylenedioxymethamphetamine on monoaminergic systems in rat brain. Eur. J. Pharmacol. 128, 41-48.
7. Stone, D. M., Merchant, K. M., Hanson, G. R., and Gibb, J. W. (1987) Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26, 1677-1683.
8. Stone, D. M., Johnson, M., Hanson, G. R., and Gibb, J. W. (1989) Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulfhydryl sites. Eur. J. Pharmacol. 172, 93-97.
9. Ricaurte, G. A., Bryan, G., Strauss, L., Seiden, L., and Schuster, C. (1985) Hallucinogenic amphetamine selectively destroys brain serotonergic nerve terminals. Science 229, 986-988.
10. Commins, D. L., Vosmer, G., Virus, R. M., Woolverton, W. L., Schuster, C. R., and Seiden, L. S. (1987) Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in rat brain. J. Pharmacol. Exp. Ther. 241, 338-345.
11. 3H]-paroxetine-labeled serotonin uptake sites. J. Pharmacol. Exp. Ther. 242, 911-916.
12. Lew, R., Sabol, K. E., Chou, C., Vosmer, G. L., Richards, J., and Seiden, L. S. (1996) Methylenedioxymethamphetamnine-induced serotonin deficits are followed by partial recovery over 52-week period. Part II: Radioligand binding and autoradiography studies. J. Pharmacol. Exp. Ther. 276, 855-865.
13. O'Hearn, E., Battaglia, G., De Souza, E. B., Kuhar, M. J., and Molliver, M. E. (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. Neuroscience 8, 2788-2803.
14. Ricaurte, G. A., Delanney, L. E., Irwin, I., and Langston, J. W. (1988) Toxic effects of MDMA on central serotonergic neurons in primate: importance of route and frequency of drug administration. Brain Res. 446, 165-168.
15. Molliver, M. E., O'Hearn, E., Battaglia, G., and DeSouza, E. B. (1986) Direct intracerebral administration of MDA and MDMA does not produce serotonin neurotoxicity. Soc. Neurosci. Abstr. 12, 1234.
16. Schmidt, C. J., and Taylor, V. L. (1988) Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons. Eur. J. Pharmacol. 156, 121-131.
17. Paris, J. M., and Cunningham, K. A. (1992) Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA). Brain Res. Bull. 28, 115-119.
18. Gollamudi, R., Ali, S. F., Lipe, G., Newport, G., Webb, P., Lopez, M., Leakey, J. E., Kolta, M., and Slikker, W., Jr. (1989) Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA. Neurotoxicology 10, 455-466.
19. McCann, U. A., and Ricaurte, G. A. (1991) Major metabolites of 3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons. Brain Res. 543, 279-282.
20. Zhao, Z., Castagnoli, N., Jr., Ricaurte, G. A., Steele, T., and Martello, M. (1992) Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl]propane [(methylenedioxy)-methamphetamine]. Chem. Res. Toxicol. 5, 89-94.
21. Midha, K. K., Hubbard, J. W., Bailey, K., and Cooper, J. K. (1978) α-Methyldopamine, a key intermediate in the metabolic disposition of 3,4-methylenedioxyamphetamine in vivo in dog and monkey. Drug Metab. Dispos. 6, 623-630.
22. Lim, H. K., and Foltz, R. L.(1988) In vivo and in vitro metabolism of 3,4-methylenedioxymethamphetamine in the rat: identification of metabolites using an ion trap detector. Chem. Res. Toxicol. 1, 370-378.
23. Kumagai, Y., Schmitz, D. A., and Cho, A. K. (1992) Cytochrome P450 isozymes responsible for the metabolic activation of methylenedioxymethamphetamine (MDMA) in rat. FASEB J. 6, A2567.
24. Miller, R. T., Lau, S. S., and Monks, T. J. (1997) 2,5-Bis-(glutathion-S-yl)-α-methyldopamine, a putative metabolite of (+)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations. Eur. J. Pharmacol. 323, 173-180.
25. Hiramatsu, M., Kumagai, Y., Unger, S. E., and Cho, A. K. (1990) Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J. Pharmacol. Exp. Ther. 254, 521-527.
26. Patel, N., Kumagai, Y., Unger, S. E., and Cho, A. K. (1991) Transformation of dopamine and α-methyldopamine by NG 108-15 cells: formation of thiol adducts. Chem. Res. Toxicol. 4, 421-426.
27. Miller, R. T. (1996) Metabolism-dependent bioactivation of methylenedioxyampetamine to neurotoxic quinol-thioethers. Ph.D. Thesis, University of Texas at Austin, Austin, TX.
28. Miller, R. T., Lau, S. S., and Monks, T. J. (1996) Effect of 5-(Glutathion-S-yl)-α-oxymethyldopamine on dopamine, serotonin and norepinepherine concentrations following intracerebroventricular administration to male Sprague-Dawley rats. Chem. Res. Toxicol. 9, 457-465.
29. Miller, R. T., Lau, S. S., and Monks, T. J. (1995) Metabolism of 5-(Glutathion-S-yl)-α-methyldopamine following intracerebroventricular administration to male Sprague-Dawley rats. Chem. Res. Toxicol. 8, 634-641.
30. Monks, T. J., and Lau, S. S. (1997) Biological reactivity of polyphenolic-glutathione conjugates. Chem. Res. Toxicol. 10, 1296-1313.
31. Cadet, J. L., Ladenheim, B., Hirata, H., Rothman, R. B., Ali, S., Carlson, E., Epstein, C., and Moran, T. H. (1995) Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): evidence from using CuZn-superoxide dismutase transgenic mice. Synapse 21, 169-176.
32. Mulligan, K. A., and Tork, I. (1988) Serotoninergic innervation of the cat cerebral cortex. J. Comp. Neurol. 270, 86-110.
33. Tork, I. (1990) Anatomy of the serotonergic system. Ann. N.Y. Acad. Sci. 600, 9-34.
34. Kosofsky, B. E., and Molliver, M. E. (1987) The serotoninergic innervation of cerebral cortex: different classes of axon terminals arise from dorsal and median raphe nuclei. Synapse 1, 153-168.
35. Mamounas, L. A., Mullen, C. A., O'Hearn, E., and Molliver, M. E. (1991) Dual serotoninergic projections to forebrain in the rat: morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J. Comp. Neurol. 314, 558-586.
36. Molliver, M. E. (1987) Serotonergic neuronal systems: what their anatomic organization tells us about function. J. Clin. Psychopharmacol. 7 (Suppl. 6), 3S-23S.
37. Schmidt, C. J., Black, C. K., and Taylor, V. L. (1990) Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. Eur. J. Pharmacol. 181, 59-70.
38. Sprague, J. E., and Nichols, D. E. (1995) The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxyamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J. Pharmacol. Exp. Ther. 273, 667-673.
39. Baez, S., Segura-Aguilar, J., Widersten, M., Johansson, A. S., and Mannervik, B. (1997) Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem. J. 324, 25-28.
40. Segura-Aguilar, J., Baez, S., Widersten, M., Welch, C. J., and Mannervik, B. (1997) Human class Mu glutathione transferases, in particular isoenzyme M2-2, catalyze detoxication of the dopamine metabolite aminochrome. J. Biol. Chem. 272, 5727-5731.
41. Montine, T. J., Picklo, M. J., Amarnath, V., Whetsell, W. O., Jr., and Graham, D. G. (1997) Neurotoxicity of endogenous cysteinylcatechols. Exp. Neurol. 48, 26-33.
42. Shen, X.-M., and Dryhurst, G. (1996) Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: Reaction pathways of potential relevance to Parkinson's disease. Chem. Res. Toxicol. 9, 751-763.
43. Shen, X.-M., Xia, B., Wrona, M. Z., and Dryhurst, G. (1996) Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: Possible metabolites of relevance to Parkinson's disease. Chem. Res. Toxicol. 9, 1117-1126.
44. Li, H., and Dryhurst, G. (1997) Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1): a putative nigral endotoxin of relevance to Parkinson's disease. J. Neurochem. 69, 1530-1541.
45. Shen, X.-M., Zhang, F., and Dryhurst, G. (1996) Oxidation of dopamine in the presence of cysteine: Characterization of new toxic products. Chem. Res. Toxicol. 9, 751-763.
46. Li, H., Shen, X. M., and Dryhurst, G. (1998) Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of Parkinson's disease. J. Neurochem. 71, 2049-2062.
47. Monks, T. J., Ghersi-Egea, J.-F., Philbert, M. A., Cooper, A. J. L., and Lock, E. A. (1999) The role of glutathione in neuroprotection and neurotoxicity. Toxicol. Sci. 51, 161-177.
48. Monks, T. J., and Lau, S. S. (1990) Glutathione conjugation, γ-glutamyl transpeptidase and the mercapturic acid pathway as modulators of 2-bromohydroquinone oxidation. Toxicol. Appl. Pharmacol. 103, 557-563.
49. Stone, D. M., Johnson, M., Hanson, G. R., and Gibb, J. W. (1988) Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 247, 79-87.
50. 2 receptors. Brain Res. 529, 85-90.
51. 2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: Reversal by L-DOPA. J. Pharmacol. Exp. Ther. 256, 230-235.